KINE-101D

KINE-101D is a preclinical-stage peptide therapeutic being developed by Kine Science for the treatment of non-alcoholic steatohepatitis (NASH). It is part of the company's proprietary 'Kine-peptide' platform, which utilizes peptides derived from the active sites of regulatory cytokines to modulate immune and inflammatory responses. KINE-101D is specifically designed to address hepatic inflammation and fibrosis, likely by mimicking the activity of Interleukin-10 (IL-10), a potent anti-inflammatory cytokine. By targeting the IL-10 receptor, the drug aims to restore immune homeostasis in the liver and halt the progression of NASH to more severe stages like cirrhosis. As of early 2024, the candidate remains in preclinical development.